mind & bodyScienceDaily

An anti-aging drug may help protect the brain before Alzheimer's symptoms begin

from ScienceDaily

A surprising new study suggests that an anti-aging drug could help protect people genetically predisposed to Alzheimer's disease. Researchers found that just four weeks of low-dose rapamycin improved brain blood flow in healthy middle-aged adults carrying the high-risk APOE4 gene variant, with women showing the strongest benefits. Because declining blood flow can occur years before Alzheimer's symptoms appear, the discovery raises hopes for preventing or delaying the disease before memory loss begins.

explained

Sirolimus, also known as rapamycin and sold under the brand name Rapamune among others, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection, treat a rare lung disease called lymphangioleiomyomatosis, and treat perivascular epithelioid cell tumour (PEComa). It has immunosuppressant functions in humans and is especially useful in preventing the rejection of kidney transplants. It is a mammalian target of rapamycin (mTOR) kinase inhibitor that reduces the sensitivity of T cells and B cells to interleukin-2 (IL-2), inhibiting their activity.

This compound also has a use in cardiovascular drug-eluting stent technologies to inhibit restenosis.

From Wikipedia: Sirolimus (CC BY-SA 4.0) ↗
so what

Alzheimer's is often diagnosed only after significant damage has occurred, so early protective strategies are a major goal. If rapamycin proves beneficial in larger trials, it could offer a way to intervene before memory loss starts. Researchers still need longer studies to confirm safety and effectiveness.

fun fact

Rapamycin was first isolated from soil bacteria collected on Easter Island, whose local name is Rapa Nui.

more on this

Illustrative photo · Vaccinationist, Public domain, via Wikimedia Commons